Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 9:00 a.m. PDT on Thursday, October 30, 2008, at the 7th Annual BIO Investor Forum in San Francisco.

The update will include information about Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

The audio only webcast will be available at the following website address: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GERN&item_id= 1995941. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) The replay will be available approximately one hour after the live presentation and is accessible for one calendar year.

Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.

Contacts:

Geron Corporation
Anna Krassowska, 650-473-7765
Investor and Media Relations
info@geron.com